
Thymosin alpha 1, also called thymalfasin, is an immune-modulating peptide used for selected specialist-directed purposes in some countries. Its approval status and recognised indications vary considerably, so treatment should only be considered after confirming local regulatory approval.
| Generic Name | Thymosin Alpha |
| Strength | 1.6 mg |
| Manufacturer | Gufic Bioscience Limited |
| Packing | 1 vial |
| Prescribed For | Hepatitis B virus (HBV) infection |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, Japan, UAE, Saudi Arabia, Qatar, Kuwait, Georgia, Mexico, and many other countries. |




Thymosin alpha 1 is an immune-modulating peptide that influences the development and activity of T lymphocytes. It may also support dendritic cells, natural killer cells and other immune responses. Its clinical role and approved indications differ between countries.
Thymosin alpha-1 authorization, indications, availability and pricing vary substantially between countries. Major national databases may not provide a public price or reimbursement listing. The following resources provide regulatory and clinical background information.
Dr. Alka Yadav Jain is a qualified physician with professional experience in viral infection care and medication management. Her areas of interest include antiviral therapies, responsible prescribing, monitoring treatment response and supporting the safe use of medicines.
Disclaimer
This website operates in compliance with applicable pharmaceutical laws. All content and data available on this website are intended solely for informational purposes. The information provided is not a substitute for professional medical advice, diagnosis, or treatment. Information provided here is for general awareness and does not replace medical advice. We strongly encourage you to consult a qualified healthcare professional for guidance.